IC
JAZZ icon

Ikarian Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ikarian Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,460
Closed -$2.36M – 171
2026
Q1 		$2.36M Sell
12,460
-147,907
-92% -$25.8M 0.19% 94
2025
Q4 		$27.3M Buy
160,367
+82,567
+106% +$12.7M 2.13% 8
2025
Q3 		$10.3M Buy
77,800
+37,800
+95% +$4.53M 1.04% 25
2025
Q2 		$4.24M Buy
+40,000
New +$4.35M 0.82% 38

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Ikarian Capital's JAZZ Position: Q2 2026 in Review

Ikarian Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 12,460 shares — an estimated $2.36M sold.

Ikarian Capital first reported a position in JAZZ in Q2 2025 and held it in 4 quarters. The position peaked at $27.3M in Q4 2025. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Ikarian Capital reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Ikarian Capital sold 12,460 Jazz Pharmaceuticals shares in Q2 2026, an estimated $2.36M.
  • Ikarian Capital first reported a position in Jazz Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Ikarian Capital's Jazz Pharmaceuticals position peaked at $27.3M in Q4 2025.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.